Welcome to our dedicated page for Xencor news (Ticker: XNCR), a resource for investors and traders seeking the latest updates and insights on Xencor stock.
Xencor, Inc. (NASDAQ: XNCR) is a clinical-stage biopharmaceutical company developing engineered antibodies for cancer and autoimmune diseases, and its news flow reflects both internal pipeline progress and partner-driven milestones. The company regularly issues updates on its XmAb® drug candidates, including T-cell engaging bispecific antibodies and Fc-engineered antibodies that use its XmAb and Xtend™ technologies.
Investors following XNCR news can expect detailed announcements on clinical trial progress across oncology and autoimmune indications. Recent releases have covered Phase 1 and Phase 2 studies of programs such as XmAb819 for advanced clear cell renal cell carcinoma, XmAb541 for gynecologic and germ cell tumors, plamotamab for rheumatoid arthritis, XmAb657 for idiopathic inflammatory myopathies, and XmAb942 and XmAb412 for inflammatory bowel and other autoimmune diseases. These updates often include safety and efficacy summaries, dose-escalation status, and plans for pivotal or proof-of-concept studies.
Xencor’s news stream also features financial results and guidance, including quarterly earnings, cash and marketable securities levels, and commentary on how its balance sheet supports research and development plans. In addition, the company reports on intellectual property developments, such as U.S. patent issuances that extend royalty terms on Xtend-based antibodies like Ultomiris, and on collaboration milestones with partners including Amgen, Astellas, Incyte and Zenas Biopharma.
Corporate governance and strategic updates, such as board appointments and participation in investor conferences, are also common topics. For investors and analysts, the XNCR news page provides a centralized view of how Xencor’s XmAb technology platform is progressing in the clinic, how partnered programs are advancing, and how these activities translate into milestones, royalties and long-term development plans.
Xencor, Inc. (NASDAQ: XNCR) will release its third quarter 2021 financial results after market close on November 8, 2021. The management will conduct a webcast and conference call at 4:30 p.m. ET to discuss results and provide a corporate update. Investors can access the call by dialing (877) 359-9508 for domestic callers or (224) 357-2393 for international callers. The call will also be available via a live webcast on their website, archived for 30 days.
Xencor has entered a second collaboration with Janssen Biotech to develop plamotamab, a bispecific antibody targeting CD20 x CD3 for B-cell malignancies. The deal includes a
Xencor, Inc. (NASDAQ:XNCR) announced five poster presentations at the Society for Immunotherapy of Cancer's annual meeting from November 10-14, 2021. Key topics include clinical results for vudalimab, a PD-1 x CTLA-4 bispecific antibody, in various cancers, and data on preclinical programs targeting IL-12, PD-L1, TGFβR2, and NK cell engagement. The company aims to advance its dual checkpoint therapy in Phase 2 trials for advanced prostate cancer and gynecologic malignancies, indicating potential growth in its oncology pipeline.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on engineered monoclonal antibodies and cytokines, will present at the Cantor Virtual Global Healthcare Conference on September 27, 2021, at 4:00 p.m. ET. The event will be available via live webcast in the Investors section of their website. Xencor is currently developing 22 clinical candidates using its XmAb® technology, which enhances protein structure for innovative therapeutic actions. A replay of the presentation will be accessible for 30 days post-event.
Xencor, a clinical-stage biopharmaceutical company, reported significant financial results for Q2 2021, with total revenue soaring to $67.4 million, up from $13.1 million year-on-year. The company initiated a Phase 2 study for XmAb717 in metastatic prostate cancer and plans further studies for other drug candidates. R&D expenses increased to $49.5 million, reflecting ongoing development efforts. Xencor achieved a net income of $52.2 million, a turnaround from a net loss of $35 million in Q2 2020. The company aims to maintain cash reserves between $475 million and $500 million by year-end.
Xencor, a clinical-stage biopharmaceutical company focused on engineered monoclonal antibodies and cytokines for treating cancer and autoimmune diseases, has announced its participation in several investor events.
- Bernstein CD28 Day: Presentation on August 9 at 1:00 p.m. ET.
- Wedbush PacGrow Healthcare Conference: Panel on August 10 at 1:10 p.m. ET.
- BTIG Virtual Biotechnology Conference: Presentation on August 10 at 3:30 p.m. ET.
- Canaccord Genuity Conference: Presentation on August 11 at 4:30 p.m. ET.
- Piper Sandler West Coast Bus Tour: Presentation on August 12 at 4:00 p.m. ET.
A webcast of the Canaccord presentation will be available on Xencor's website.
Xencor, Inc. (NASDAQ: XNCR) will release its second quarter 2021 financial results post-market on August 4, 2021. A conference call is scheduled for 4:30 p.m. ET to discuss these results and provide a corporate update. The live call can be accessed via phone or a webcast on the company's website. Xencor is a clinical-stage biopharmaceutical firm focusing on engineered monoclonal antibodies and cytokines targeting cancer and autoimmune diseases, with 22 candidates in clinical development leveraging its XmAb® technology.
Xencor, Inc. (NASDAQ: XNCR) announced that Dr. Bassil Dahiyat, president and CEO, will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 1:00 p.m. ET. The presentation will cover Xencor's focus on developing engineered monoclonal antibodies and cytokines for cancer and autoimmune diseases. A webcast of the event will be available on the company's website, with a replay accessible for at least 30 days following the event.
Xencor, Inc. (NASDAQ: XNCR) announced that the FDA has granted emergency use authorization for sotrovimab, an engineered monoclonal antibody developed with Vir Biotechnology and GlaxoSmithKline to treat mild-to-moderate COVID-19 in high-risk patients. While not approved, sotrovimab shows an 85% reduction in hospitalization or death based on Phase 3 trial data. Xencor has licensed its Xtend technology to Vir to enhance antibody performance. The EUA will last as long as the COVID-19 emergency declaration is in effect.
Xencor, a clinical-stage biopharmaceutical company (NASDAQ:XNCR), entered a licensing agreement with Bristol-Myers Squibb (NYSE:BMY) for its Xtend™ Fc technology to extend the half-life of the SARS-CoV-2 mAb Duo, designed for COVID-19 treatment. This antibody combination, discovered at Rockefeller University, is currently in Phase 1 clinical evaluation. Xencor, eligible for royalties from sales, emphasizes that its technology improves therapeutic performance, potentially lowering costs for antiviral therapies. The partnership aims to address urgent medical needs, particularly in the pandemic context.